Chemestmed OÜ
Unique value
Chemestmed is the first in the world to develop targeted small-molecule drugs that enhance RNA methylation. In 2019, we discovered compounds that chemically increase the activity of the methyltransferase METTL3, thereby improving mRNA methylation. This represents a novel and underexplored mechanism whose role in metabolic and neurodegenerative diseases is becoming increasingly recognized. Our platform-based approach combines chemistry, molecular biology, and AI-driven drug design to deliver new therapeutic solutions for diseases that currently lack effective treatment options.
Looking for
Collaboration partners, investors, scientists, research partners, and contacts within pharmaceutical companies.
Services / Focus area
Chemestmed is a biotechnology company developing innovative small-molecule drug candidates for the treatment of metabolic and central nervous system disorders associated with RNA methylation dysregulation, such as obesity, anxiety disorders, cancer, Parkinson’s disease, and Alzheimer’s disease.
